Bloom Health Partners (CSE: BLMH) is one company whose earnings appear to be flying under the radar in the midst of this bear market.
The company recently posted Q2 earnings of $11.1 million, which eclipses its current valuation of $8.2 million.
In his 2022 guidance, CEO Andrew Morton stated that Bloom is projected to bring in $25-$28 million in revenue for the year. With this Q2 performance, it appears the company is well on track to reach this.
It will be worth keeping an eye out for contract acquisition announcements from the company to show that it is continuing growth. If Q3 performance is comparable to Q2, I expect shares won't stay discounted for long.
$BLMH.c is currently trading at $.21, up 7% today.
https://ceo.ca/@newsfile/bloom-health-partners-reports-profitable-fiscal-q2